CN102429920A - Multi-correlation ascorbic acid reducing composition and preparation method thereof - Google Patents
Multi-correlation ascorbic acid reducing composition and preparation method thereof Download PDFInfo
- Publication number
- CN102429920A CN102429920A CN2011103880777A CN201110388077A CN102429920A CN 102429920 A CN102429920 A CN 102429920A CN 2011103880777 A CN2011103880777 A CN 2011103880777A CN 201110388077 A CN201110388077 A CN 201110388077A CN 102429920 A CN102429920 A CN 102429920A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- effervescent
- acid
- falls
- acid compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 title abstract 4
- 235000010323 ascorbic acid Nutrition 0.000 title abstract 4
- 239000011668 ascorbic acid Substances 0.000 title abstract 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 239000011573 trace mineral Substances 0.000 claims abstract description 14
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 6
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 claims description 17
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 claims description 17
- 239000001654 beetroot red Substances 0.000 claims description 17
- 235000012677 beetroot red Nutrition 0.000 claims description 17
- 235000002185 betanin Nutrition 0.000 claims description 17
- 239000007938 effervescent tablet Substances 0.000 claims description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 17
- 206010013786 Dry skin Diseases 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 239000007779 soft material Substances 0.000 claims description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 229960001375 lactose Drugs 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 13
- 229920003081 Povidone K 30 Polymers 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229930003270 Vitamin B Natural products 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 235000019156 vitamin B Nutrition 0.000 claims description 9
- 239000011720 vitamin B Substances 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 7
- 108010011485 Aspartame Proteins 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 5
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000011478 zinc gluconate Nutrition 0.000 claims description 5
- 239000011670 zinc gluconate Substances 0.000 claims description 5
- 229960000306 zinc gluconate Drugs 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 229960004106 citric acid Drugs 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- 230000022558 protein metabolic process Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 1
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 101150026579 CBS gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- -1 amines alkaloid Chemical class 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a multi-association ascorbic acid reducing composition and a preparation method thereof. The multi-correlation ascorbic acid composition is prepared from main raw materials of betaine, vitamins and trace elements. The multi-correlation ascorbic acid composition can be used for reducing the content of homocysteine in blood of a human body, timely supplementing necessary full-methyl nutrients in the protein metabolism process of the human body, enabling the human body to be in the optimal nutritional state and converting potential health risks into the health state to the greatest extent.
Description
Technical field
The present invention relates to a kind of many associations and fall the hematic acid composition and method of making the same.
Background technology
(Hyperhomocysteinaemia Hhcy) is meant the blood-plasma total homocysteine concentration this pathologic condition that raises to hyperhomocysteinemiainjury, is also referred to as high hematic acid disease.Lots of clinical and epidemiology evidence show; Hhcy is sudden death, diabetes, osteoporosis, alzheimer disease, tumor, the odd-shaped independent hazard factor of neonate; And it is, directly related like coronary heart disease, apoplexy, hypertension, aneurysm, thrombotic disease with carrying out property peripheral vascular disease and atherosclerotic angiopathy.
Homocysteine (Hcy) is a kind ofly to be generated by the methionine demethylation in vivo from the deutero-mercaptoamino acid that contains of methionine metabolism, is found first by DeVgneaud in 1932.In human body cell, Hcy has three kinds of metabolic pathways:
1, methyl approach again.In various tissues, Hcy is by methionine synthase catalysis in the cell, and methyl changes into methionine again, and this course of reaction needs VitB
12Participation, and by N-5, the methyl tetrahydrofolate that 10-MTHFR (MTHFR) catalysis forms provides methyl.Methylated again another approach of Hcy is confined in the hepatocyte, and betanin provides methyl, under betanin-Hcy invertase catalysis, accomplishes the synthetic of methionine.
In addition, VitB
2As the coenzyme of MTHFR, be negative correlation with Plasma Hcy concentration, its shortage is one of cause of disease that causes Hhcy.
2, change the sulfuration approach.Hcy is by cystathionie-β synzyme (CBS) catalysis, VitB in the cell
6, zinc is cofactor, forms cystathionie with the serine condensation, cystathionie further is cracked into cystine and α-ketone butanoic acid again under gamma cystathionase catalysis.α-ketone butanoic acid can be transformed into mono succinate acyl coenzyme A, generates glucose through tricarboxylic acid cycle.
3, be discharged into the extracellular.Synthetic Hcy can also be directly released in the extracellular matrix, forms certain Hcy blood concentration.
Literature research confirms, possibly cause the factor of Hhcy to have: (1) trophic factor: like folic acid, VitB
12, VitB
6Lack.(2) inherited genetic factors: mthfr gene and cbs gene etc. isozygotys and heterozygous mutation, and is older.(3) environmental factors: pressure is big, have a sleepless night, get angry, drink and smoking etc.In clinical research, also confirm trophic factor such as folic acid, VitB
6And VitB
12Content directly influences the concentration of Plasma Hcy, and the patient is given folic acid or folic acid and VitB
6, VitB
12Drug combination can effectively reduce Plasma Hcy concentration.
Betanin is a kind of quaternary amine type water-soluble alkaloid, gains the name because of from Radix Betae, extracting at first, and chemistry trimethylamine second lactone by name, molecular structure is fairly simple, is methyl (CH
3) donor, more similar with methionine, choline chemical constitution, all belong to the quaternary amine alkaloids, can partly substitute these nutrients.
The purposes of betanin is except its pharmacological action comprises AFL, antitumor, blood pressure lowering, anti-peptic ulcer and gastrointestinal dysfunction; One of its most important application is as the vitamin additive; It is as a kind of high-efficiency activated methyl donor biological nutrient; Have the protein of promotion and lipid metabolism, stable vitamin prevents effects such as fatty liver.
The above nutrient substance can reduce homocysteine separately mostly, and discover, when one of which was worked, the effect of falling homocysteine was better, and its effect is more significantly than all single effect sums.Therefore, be raw material like how betanin and vitamin, in order to reducing people's height hematic acid, prevention Hhcy is everybody problem for paying close attention to deeply, and special hope can be developed and is easy to take, and hematic acid compositions effervescent tablet falls in portable many associations.
Summary of the invention
The purpose of this invention is to provide a kind of easy absorption, the hematic acid composition and method of making the same falls in many associations delicious, easy to use.
The invention provides a kind of many associations and fall the hematic acid compositions, many associations of the present invention are fallen the hematic acid compositions and are comprised vitamin, betanin, trace element, and the weight proportion of each component is:
Vitamin 15-55%
Betanin 40-80%
Trace element 0.1-5%.
The hematic acid compositions falls in many associations of the present invention, it is characterized in that vitamin comprises folic acid and vitamin B
2, vitamin B
6, vitamin B
12, any or two or more compositionss in the vitamin C.
The hematic acid compositions falls in many associations of the present invention, it is characterized in that vitamin B
2, vitamin B
6Weight ratio be 1:1.
The hematic acid compositions falls in many associations of the present invention, it is characterized in that trace element comprises zinc gluconate.
The hematic acid compositions falls in many associations of the present invention, it is characterized in that being prepared into chewable tablet and effervescent tablet.
Hematic acid compositions effervescent tablet falls in many associations of the present invention, it is characterized in that the weight proportion that adds adjuvant is:
Vitamin 8-20%
Betanin 4-15%
Trace element 0.1-1%
Effervescent acid source 15-40%
Effervescent carbon dioxide source 15-40%
Diluent 8-20%
Binding agent 0.5-2%
Flavoring agent 0.3-2%
Lubricant 15-40%.
Hematic acid compositions effervescent tablet falls in many associations of the present invention, it is characterized in that wherein said effervescent acid source comprises anhydrous citric acid, tartaric acid, malic acid citric acid or fumaric acid; The effervescent carbon dioxide source comprises sodium bicarbonate, potassium bicarbonate or sodium carbonate.
Hematic acid compositions effervescent tablet falls in many associations of the present invention, it is characterized in that wherein said diluent comprises sorbitol, mannitol or lactose; Binding agent comprises 30 POVIDONE K 30 BP/USP 30, starch; Flavoring agent comprises sucrose, lactose, stevioside or aspartame; Lubricant comprises polyethylene glycol 6000, Macrogol 4000 or magnesium stearate.
Another object of the present invention provides the method for preparing that hematic acid compositions effervescent tablet falls in a kind of many associations, and its preparation process comprises:
(1) get the effervescent carbon dioxide source and add fused mix lubricant, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of sweeting agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 1;
(2) get the quaternary amines alkaloid and add fused mix lubricant, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of flavoring agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 2;
(3) get vitamin, trace element, effervescent acid source, diluent, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of sweeting agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 3;
(4), add lubricant with granule 1,2,3 mix homogeneously;
(5) tabletting, packing promptly get effervescent tablet.
Product of the present invention can be used for reducing human body homocysteine content; Be used for replenishing the vitamin of needed by human simultaneously; Be of value to enhancing human immune; Promote health, especially for hyperhomocysteinemiainjury crowd and physical weakness, suffer from crowds such as tumor, fatty liver, hypertension and have remarkable health care.
Product of the present invention can be the chewable tablet type, helps the absorption of human nutrition composition, and this product appearance is beautiful, special taste, pleasant.
Product of the present invention also can be effervescent tablet preparation formulation, meets the water generates carbon dioxide, makes the loose rapidly disintegrate of granule; Take with the solution form, taking convenience, nutritional labeling is rapid-action; Be prone to absorb, improved bioavailability greatly, this dosage form also more is suitable for the crowd of child, old people and the solid preparation of should not swallowing; The old and the young like that vast market prospect is arranged.
The specific embodiment
Below further describe the present invention through embodiment, it should be understood that these embodiment only are used for the purpose of illustration, certainly do not limit the scope of the invention.
Embodiment 1
Take by weighing supplementary material by following proportioning: betanin 200g, folic acid 0.2g, vitamin C 130g, vitamin B
22.5g, vitamin B
62.5g, zinc gluconate 4g, malic acid 150g, tartaric acid 220g, sodium bicarbonate 320g, lactose 315g, starch 60g, Macrogol 4000 255g.
Method for preparing is following:
(1) get sodium bicarbonate and add fused Macrogol 4000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% starch of an amount of lactose, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 1;
(2) get betanin and add fused Macrogol 4000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% starch of an amount of lactose, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 2;
(3) get vitamin, trace element, effervescent acid source, lactose, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% starch of an amount of lactose, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 3;
(4), add lubricant with granule 1,2,3 mix homogeneously;
(5) tabletting, packing promptly get effervescent tablet.
Embodiment 2
Take by weighing raw material by following proportioning: betanin 230g, folic acid 0.2g, vitamin C 125g, vitamin B
22.5g, vitamin B
62.5g, zinc gluconate 5g, tartaric acid 430g, sodium bicarbonate 380g, lactose 250g, 30 POVIDONE K 30 BP/USP 30 30g, stevioside 15g, polyethylene glycol 6000 310g.
Method for preparing is following:
(1) get sodium bicarbonate and add fused polyethylene glycol 6000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of stevioside, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 1;
(2) get betanin and add fused polyethylene glycol 6000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of stevioside, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 2;
(3) get vitamin, trace element, effervescent acid source, lactose, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of stevioside, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 3;
(4), add lubricant with granule 1,2,3 mix homogeneously;
(5) tabletting, packing promptly get effervescent tablet.
Embodiment 3
Take by weighing raw material by following proportioning: betanin 280g, folic acid 0.2g, vitamin C 125g, vitamin B
22.5g, vitamin B
62.5g, vitamin B
120.02g, zinc gluconate 5g, tartaric acid 430g, citric acid 120g, sodium bicarbonate 420g, lactose 250g, 30 POVIDONE K 30 BP/USP 30 120g, aspartame 15g, polyethylene glycol 6000 300g.
Method for preparing is following:
(1) get sodium bicarbonate and add fused polyethylene glycol 6000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of aspartame, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 1;
(2) get betanin and add fused polyethylene glycol 6000 mixing, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of aspartame, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 2;
(3) get vitamin, trace element, effervescent acid source, lactose, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% 30 POVIDONE K 30 BP/USP 30 of an amount of aspartame, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 3;
(4), add lubricant with granule 1,2,3 mix homogeneously;
(5) tabletting, packing promptly get effervescent tablet.
Claims (9)
1. the hematic acid compositions falls in association more than one kind, it is characterized in that comprising vitamin, betanin, trace element, and the weight proportion of each component is:
Vitamin 15-55%
Betanin 40-80%
Trace element 0.1-5%.
2. the hematic acid compositions falls in the described many associations of claim 1, it is characterized in that vitamin comprises folic acid and vitamin B
2, vitamin B
6, vitamin B
12, any or two or more compositionss in the vitamin C.
3. the hematic acid compositions falls in the described many associations of claim 2, it is characterized in that vitamin B
2, vitamin B
6Weight ratio be 1:1.
4. the hematic acid compositions falls in the described many associations of claim 1, it is characterized in that trace element comprises zinc gluconate.
5. the hematic acid compositions falls in the described many associations of claim 1, it is characterized in that being prepared into effervescent tablet and chewable tablet.
6. hematic acid compositions effervescent tablet falls in the described many associations of claim 5, it is characterized in that the weight proportion of each component is:
Vitamin 4-15%
Betanin 8-20%
Trace element 0.1-1%
Effervescent acid source 15-40%
Effervescent carbon dioxide source 15-40%
Diluent 8-20%
Binding agent 0.5-2%
Flavoring agent 0.3-2%
Lubricant 15-40%.
7. hematic acid compositions effervescent tablet falls in the described many associations of claim 6, it is characterized in that wherein said effervescent acid source comprises anhydrous citric acid, tartaric acid, malic acid citric acid or fumaric acid; The effervescent carbon dioxide source comprises sodium bicarbonate, potassium bicarbonate or sodium carbonate.
8. hematic acid compositions effervescent tablet falls in the described many associations of claim 6, it is characterized in that wherein said diluent comprises sorbitol, mannitol or lactose; Binding agent comprises 30 POVIDONE K 30 BP/USP 30, starch; Flavoring agent comprises sucrose, lactose, stevioside or aspartame; Lubricant comprises polyethylene glycol 6000, Macrogol 4000 or magnesium stearate.
9. one kind prepares the method that hematic acid compositions effervescent tablet falls in many associations as claimed in claim 6, and its preparation process comprises:
1. get the effervescent carbon dioxide source and add fused mix lubricant, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of sweeting agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 1;
2. get betanin and add fused mix lubricant, after the cooling, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of sweeting agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 2;
3. get vitamin, trace element, effervescent acid source, diluent, pulverize, 100 order mix homogeneously mix with the interior dehydrated alcohol that adds 10% binding agent of an amount of flavoring agent, the system soft material, and 20 orders are granulated, and 45 ℃ of dryings get granule 3;
4. with granule 1,2,3 mix homogeneously, add lubricant;
5. tabletting, packing promptly get effervescent tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103880777A CN102429920A (en) | 2011-11-30 | 2011-11-30 | Multi-correlation ascorbic acid reducing composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103880777A CN102429920A (en) | 2011-11-30 | 2011-11-30 | Multi-correlation ascorbic acid reducing composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102429920A true CN102429920A (en) | 2012-05-02 |
Family
ID=45978506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103880777A Pending CN102429920A (en) | 2011-11-30 | 2011-11-30 | Multi-correlation ascorbic acid reducing composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102429920A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141776A (en) * | 2013-03-15 | 2013-06-12 | 肖海 | Nutrient compound and application thereof |
| CN109843270A (en) * | 2016-10-20 | 2019-06-04 | 固荣私人有限公司 | Oral drug preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087517A (en) * | 1992-09-14 | 1994-06-08 | 韦斯塔药品有限公司 | Be used to reduce the pharmaceutical preparation of homocysteine levels |
| CN101239069A (en) * | 2007-02-05 | 2008-08-13 | 广州和竺生物科技有限公司 | Application of compound capable of supplying active methyl or engaging in methyl migration |
| CN101406478A (en) * | 2007-10-10 | 2009-04-15 | 北京华安佛医药研究中心有限公司 | Pharmaceutical composition for reducing homosysteine |
| CN102099044A (en) * | 2008-05-16 | 2011-06-15 | 益生菌股份公司 | Use of probiotic bacteria for the treatment of hyperhomocysteinaemia |
-
2011
- 2011-11-30 CN CN2011103880777A patent/CN102429920A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087517A (en) * | 1992-09-14 | 1994-06-08 | 韦斯塔药品有限公司 | Be used to reduce the pharmaceutical preparation of homocysteine levels |
| CN101239069A (en) * | 2007-02-05 | 2008-08-13 | 广州和竺生物科技有限公司 | Application of compound capable of supplying active methyl or engaging in methyl migration |
| CN101406478A (en) * | 2007-10-10 | 2009-04-15 | 北京华安佛医药研究中心有限公司 | Pharmaceutical composition for reducing homosysteine |
| CN102099044A (en) * | 2008-05-16 | 2011-06-15 | 益生菌股份公司 | Use of probiotic bacteria for the treatment of hyperhomocysteinaemia |
Non-Patent Citations (1)
| Title |
|---|
| 林晓明 等: "《高级营养学》", 31 August 2004, article "同型半胱氨酸与叶酸", pages: 111-113 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141776A (en) * | 2013-03-15 | 2013-06-12 | 肖海 | Nutrient compound and application thereof |
| CN109843270A (en) * | 2016-10-20 | 2019-06-04 | 固荣私人有限公司 | Oral drug preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019362348A1 (en) | Micro-effervescent buccal tablet and preparation method thereof | |
| EP2393475B1 (en) | Orosoluble compositions containing at least a salt of s- adenosyl methionine (same) | |
| RU2456000C2 (en) | Mixed iron and copper salts masking metallic taste | |
| CN106387918A (en) | Vitamin C sodium effervescence formulation and preparation method thereof | |
| KR101892078B1 (en) | Pharmaceutical Composition for Prevention or Treatment of Brain Cancer Comprising Robarstin and Combination Therapy in the Treatment of Brain Cancer Using the Same | |
| CN103751327A (en) | Zinc gluconate VC (Vitamin C) effervescent tablet | |
| CN107028191B (en) | Vitamin composition suitable for accurate nutrition of middle-aged and elderly people | |
| CN101352255A (en) | Medlar nutrient effervescence decoction pieces and process for producing the same | |
| CN1994355A (en) | Gadol effervescence tablet | |
| CN102716149A (en) | Calcium carbonate-D3 effervescent tablet and preparation method thereof | |
| CN102266013B (en) | Fruit multi-vitamin calcium tablets and preparation method thereof | |
| CN102429920A (en) | Multi-correlation ascorbic acid reducing composition and preparation method thereof | |
| CN105902512A (en) | Olaparib effervescent tablet and preparation method thereof | |
| KR20160021547A (en) | Composition for Effervescent Tablet Containing Dandelion Extract and Preparation Method | |
| EP2227221B1 (en) | Effervescent tablets and effervescent granules containing carnitine tartrate | |
| CN116998574A (en) | Taste-masking micro-foam tablet and preparation method thereof | |
| CN102907676A (en) | Preparation method of sea-buckthorn chewable tablet | |
| CN106215175A (en) | Phycocyanin vitamin C compound effervescent tablet and preparation method thereof | |
| CN103082295A (en) | Preparation process of three-layer effervescent tablet comprising B vitamins | |
| CN105249128A (en) | Vitamin group B solid beverage | |
| CN100512799C (en) | Effervescence tablet containing multiplex vitamin including iron, zinc and calcium, ring shaped preparation and preparation method | |
| CN103860517A (en) | Ornithine aspartate effervescent tablets and preparing process thereof | |
| CN104971051A (en) | Cetilistat tablet and preparation method | |
| CN103479652B (en) | Children's four-vitamin calcium gluconate effervescent tablets and preparation method thereof | |
| CN107951034A (en) | Vitamin effervescent formulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120502 |
|
| WD01 | Invention patent application deemed withdrawn after publication |